Biocompatible Nanocomplexes for Molecular Targeted MRI Contrast Agent

详细信息    查看全文

• 作者：Zhijin Chen (1)
  Dexin Yu (2)
  Shaojie Wang (3)
  Na Zhang (1)
  Chunhong Ma (2)
  Zaijun Lu (3)
  
• 关键词：Nanocomplexes ; Molecular imaging ; Magnetic resonance imaging ; DTPA–Gd ; PLA–PEG
• 刊名：Nanoscale Research Letters
• 出版年：2009
• 出版时间：July 2009
• 年：2009
• 卷：4
• 期：7
• 页码：618-626
• 全文大小：515KB
• 参考文献：1. G. de Marco, A. Bogdanov, E. Marecos, A. Moore, M. Simonova, R. Weissleder, Radiology 208(1), 65 (1998)
  2. R. Weissleder, Radiology 212(3), 609 (1999)
  3. T.N. Nagaraja, K. Karki, J.R. Ewing, R.L. Croxen, R.A. Knight, Stroke 39, 427 (2008). doi:10.1161/strokeaha.107.496059 CrossRef
  4. H. Xu, C.A.S. Regino, Y. Koyama, Y. Hama, A.J. Gunn, M. Bernardo, H. Kobayashi, P.L. Choyke, M.W. Brechbiel, Bioconjug. Chem. 18, 1474 (2007). doi:10.1021/bc0701085 CrossRef
  5. H. Xu, C.A.S. Regino, M. Bernardo, Y. Koyama, H. Kobayashi, P.L. Choyke, M.W. Brechbiel, J. Med. Chem. 50(14), 3185 (2007). doi:10.1021/jm061324m CrossRef
  6. X.X. Wen, E.F. Jackson, R.E. Price, E.E. Kim, Q.P. Wu, S. Wallace, C. Charnsangavej, J.G. Gelovani, C. Li, Bioconjug. Chem. 15(6), 1408 (2004). doi:10.1021/Bc049910m CrossRef
  7. E. Toth, L. Helm, K.E. Kellar, A.E. Merbach, Chem. Eur. J. 5(4), 1202 (1999). doi:10.1002/(SICI)1521-3765(19990401)5:4<1202::AID-CHEM1202>3.0.CO;2-Y CrossRef
  8. W.J.M. Mulder, G.J. Strijkers, K.C. Briley-Saboe, J.C. Frias, J.G.S. Aguinaldo, E. Vucic, V. Amirbekian, C. Tang, P.T.K. Chin, K. Nicolay, Z.A. Fayad, Magn. Reson. Med. 58, 1164 (2007). doi:10.1002/mrm.21315 CrossRef
  9. J.P. Andre, E. Toth, H. Fischer, A. Seelig, H.R. Macke, A.E. Merbach, Chem. Eur. J. 5(10), 2977 (1999). doi:10.1002/(SICI)1521-3765(19991001)5:10<2977::AID-CHEM2977>3.0.CO;2-T CrossRef
  10. D. Bazile, C. Prudhomme, M.T. Bassoullet, M. Marlard, G. Spenlehauer, M. Veillard, J. Pharm. Sci. 84(4), 493 (1995). doi:10.1002/jps.2600840420 CrossRef
  11. C.A. Nguyen, E. Allemann, G. Schwach, E. Doelker, R. Gurny, J. Pharm. Sci. 254(1), 69 (2003). doi:10.1016/S0378-5173(02)00685-3 CrossRef
  12. S.S. Venkatraman, P. Jie, F. Min, B.Y. Freddy, G. Leong-Huat, Int. J. Pharm. 298(1), 219 (2005) CrossRef
  13. V.P. Torchilin, J. Control. Release 73(2-), 137 (2001). doi:S0168365901002991 CrossRef
  14. E. Nakamuraa, K. Makinoa, T. Okanob, T. Yamamotoc, M. Yokoyama, J. Control. Release 114(3), 325 (2006) CrossRef
  15. R. Gref, P. Quellec, A. Sanchez, P. Calvo, E. Dellacherie, M.J. Alonso, Eur. J. Pharm. Biopharm. 51(2), 111 (2001). doi:10.1016/S0939-6411(00)00143-0 CrossRef
  16. C. Perez, A. Sanchez, D. Putnam, D. Ting, R. Langer, M.J. Alonso, J. Control. Release 75(1-2), 211 (2001). doi:10.1016/S0168-3659(01)00397-2 CrossRef
  17. C.D. Oja, S.C. Semple, A. Chonn, P.R. Cullis, Biochim. Biophys. Acta 1281(1), 31 (1996). doi:10.1016/0005-2736(96)00003-X CrossRef
  18. T. Riley, S. Stolnik, C.R. Heald, C.D. Xiong, M.C. Garnett, L. Illum, S.S. Davis, S.C. Purkiss, R.J. Barlow, P.R. Gellert, Langmuir 17(11), 3168 (2001). doi:10.1021/la001226i CrossRef
  19. D.C. Litzinger, A.M.J. Buiting, N. Vanrooijen, L. Huang, Biochim. Biophys. Acta 1190(1), 99 (1994). doi:0005-2736(94)90038-8 CrossRef
  20. D.E. Owens, N.A. Peppas, Int. J. Pharm. 307(1), 93 (2006). doi:10.1016/j.ijpharm.2005.10.010 CrossRef
  21. E. Wisse, R.B. De Zanger, K. Charels, P. Van Der Smissen, R.S. McCuskey, Hepatology 5(4), 683 (1985). doi:10.1002/hep.1840050427 CrossRef
  22. R. Gref, G. Miralles, E. Dellacherie, Polym. Int. 48, 251 (1999). doi:10.1002/(SICI)1097-0126(199904)48:4<251::AID-PI104>3.0.CO;2-4 CrossRef
  23. K. Ogawara, M. Yoshida, K. Higaki, T. Kimura, K. Shiraishi, M. Nishikawa, Y. Takakura, M. Hashida, J. Control. Release 59, 15 (1999). doi:S0168365999000152 CrossRef
  24. J.A. Libera, H. Cheng, M.O. Cruz, M.J. Bedzyk, J. Phys. Chem. B 109(48), 23001 (2005). doi:10.1021/jp0534941 CrossRef
  25. F. Molnar, J. Rieger, Langmuir 21(2), 786 (2005). doi:10.1021/la048057c CrossRef
  26. R. Messina, C. Holm, K. Kremer, J. Chem. Phys. 117(6), 2947 (2002). doi:10.1063/1.1490595 CrossRef
  27. K.F. Pirollo, J. Dagata, P. Wang, M. Freedman, A. Vladar, S. Fricke, L. Ileva, Q. Zhou, E.H. Chang, Mol. Imaging 5(1), 41 (2006). doi:10.2310/7290.2006.00005
  28. R. Gref, M. Luck, P. Quellec, M. Marchand, E. Dellacherie, S. Harnisch, T. Blunk, R.H. Muller, Colloids Surf. B Biointerfaces 18(3-), 301 (2000). doi:S0927-7765(99)00156-3 CrossRef
  29. W.R. Gombotz, W. Guanghui, T.A. Horbett, A.S. Hoffman, J. Biomed. Mater. Res. A 25(12), 1547 (1991). doi:10.1002/jbm.820251211 CrossRef
  30. K. Bergstrom, E. Osterberg, K. Holmberg, A.S. Hoffman, T.P. Schuman, A. Kozlowski, J.H. Harris, J. Biomater. Sci. Polym. Ed. 6(2), 123 (1994). doi:10.1163/156856294X00257 CrossRef
  31. G. Yu, M. Yamashita, K. Aoshima, M. Takahashi, T. Oshikawa, H. Takayanagi, S. Laurent, C. Burtea, L. Vander, L. Vander Elst, R.N. Muller, Bioorg. Med. Chem. Lett. 17(8), 2246 (2007). doi:S0960-894X(07)00117-5 CrossRef
  32. Y. Okuhata, Adv. Drug Deliv. Rev. 37(1-3), 121 (1999). doi:S0169-409X(98)00103-3 CrossRef
  
• 作者单位：Zhijin Chen (1)
  Dexin Yu (2)
  Shaojie Wang (3)
  Na Zhang (1)
  Chunhong Ma (2)
  Zaijun Lu (3)
  
  1. School of Pharmaceutical Science, Shandong University, 44 Wenhua Xi Road, 250012, Ji’nan, People’s Republic of China
  2. Department of Radiology Medicine, Affiliated Qilu Hospital, Shandong University, 44 Wenhua Xi Road, 250012, Ji’nan, People’s Republic of China
  3. School of Chemistry and Chemical Engineering, Shandong University, 27 Shanda Road, 250012, Ji’nan, People’s Republic of China
  
• ISSN：1556-276X

文摘

Accurate diagnosis in early stage is vital for the treatment of Hepatocellular carcinoma. The aim of this study was to investigate the potential of poly lactic acid–polyethylene glycol/gadolinium–diethylenetriamine-pentaacetic acid (PLA–PEG/Gd–DTPA) nanocomplexes using as biocompatible molecular magnetic resonance imaging (MRI) contrast agent. The PLA–PEG/Gd–DTPA nanocomplexes were obtained using self-assembly nanotechnology by incubation of PLA–PEG nanoparticles and the commercial contrast agent, Gd–DTPA. The physicochemical properties of nanocomplexes were measured by atomic force microscopy and photon correlation spectroscopy. The T1-weighted MR images of the nanocomplexes were obtained in a 3.0 T clinical MR imager. The stability study was carried out in human plasma and the distribution in vivo was investigated in rats. The mean size of the PLA–PEG/Gd–DTPA nanocomplexes was 187.9?±?2.30?nm, and the polydispersity index was 0.108, and the zeta potential was ?2.36?±?3.58?mV. The results of MRI test confirmed that the PLA–PEG/Gd–DTPA nanocomplexes possessed the ability of MRI, and the direct correlation between the MRI imaging intensities and the nano-complex concentrations was observed (r?=?0.987). The signal intensity was still stable within 2?h after incubation of the nanocomplexes in human plasma. The nanocomplexes gave much better image contrast effects and longer stagnation time than that of commercial contrast agent in rat liver. A dose of 0.04?mmol of gadolinium per kilogram of body weight was sufficient to increase the MRI imaging intensities in rat livers by five-fold compared with the commercial Gd–DTPA. PLA–PEG/Gd–DTPA nanocomplexes could be prepared easily with small particle sizes. The nanocomplexes had high plasma stability, better image contrast effect, and liver targeting property. These results indicated that the PLA–PEG/Gd–DTPA nanocomplexes might be potential as molecular targeted imaging contrast agent.